Publications by authors named "Nise Alessandra Carvalho Sousa"
Article Synopsis
- The study explored sleep disorders in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), focusing on hypersomnia, fatigue, risk of apnea, and restless legs syndrome.
- Conducted in Brazil from 2017 to 2020, it included 60 patients and found that a significant portion had poor sleep quality and excessive sleepiness, but a low risk for obstructive sleep apnea (OSA).
- The research concluded that while MS and NMOSD patients experience sleep issues, the frequency of restless legs syndrome is similar to that found in the general population, with no significant correlation to clinical factors like relapses or disability status.
Article Synopsis
- The Multiple Sclerosis Data Alliance (MSDA) aims to enhance the accessibility and discovery of real-world data (RWD) related to multiple sclerosis.
- The MSDA Catalogue, which is globally available, compiles detailed information about various data sources, including governance and data quality control methods, and currently features 38 data sources from five continents.
- The catalogue reveals trends in data collection, highlighting that personal and basic disease data are most commonly gathered, while aspects like fatigue and cognition measurements are less frequently recorded, ultimately aiding collaboration and reducing discovery times for MS RWD.
Background And Objectives: To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD).
Methods: The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country.
Previous infection with John Cunningham virus (JCV) increases the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (MS) undergoing treatment with natalizumab. Patients who test negative for JCV antibodies must be assessed every six months due to the risk of seroconversion. Data from the United States of America, Portugal, Holland, France, United Kingdom and Sweden have shown a strong correlation between the use of natalizumab and JCV seroconversion.
View Article and Find Full Text PDFBackground: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS).
Objective: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS.